Semaglutide vs Tirzepatide vs Retatrutide: Which GLP-1 Is Right for You?

The GLP-1 Revolution: Three Generations of Weight Loss Peptides

The landscape of pharmacological weight management has been transformed over the past decade by a class of compounds known as GLP-1 receptor agonists. What began with semaglutide's clinical dominance has evolved rapidly — first tirzepatide added a second hormonal target, then retatrutide brought a third. Each generation has produced more significant weight loss outcomes, but more mechanisms also means more complexity in terms of side effects and protocols.

This guide gives you the full picture on all three compounds so you can make an informed decision in consultation with your healthcare provider.

Understanding the Underlying Mechanisms

GLP-1 (Glucagon-Like Peptide-1)

GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food intake. It acts on GLP-1 receptors in the pancreas to enhance insulin secretion in a glucose-dependent manner, and critically, it acts on receptors in the hypothalamus and brainstem to reduce appetite and food intake. It also slows gastric emptying, which prolongs satiety after meals. All three compounds in this comparison are GLP-1 receptor agonists.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

GIP is a second incretin hormone that works alongside GLP-1 to stimulate insulin secretion. It also has direct effects on adipose tissue and may play a role in energy expenditure. Tirzepatide and retatrutide add GIP receptor agonism to their GLP-1 activity.

Glucagon

Glucagon is typically known as the counter-regulatory hormone to insulin — it raises blood glucose. However, glucagon also has significant effects on energy expenditure, fat mobilization (lipolysis), and hepatic fat metabolism. Retatrutide is unique in adding glucagon receptor agonism to GLP-1 and GIP activity, giving it a third distinct mechanism for weight loss.

Semaglutide: The Pioneer

Semaglutide was the compound that proved weekly injectable GLP-1 agonists could produce meaningful, sustained weight loss. Originally developed for type 2 diabetes management, the STEP trials established semaglutide as a genuine obesity treatment, with participants achieving an average of 14.9% body weight reduction over 68 weeks at the 2.4 mg weekly dose (the weight management dose, higher than the diabetes dose).

Key characteristics of semaglutide:

• Single mechanism: GLP-1 receptor agonism only
• Longest clinical track record of the three compounds
• Well-characterized side effect profile
• Weekly subcutaneous injection
• Average weight loss: 12–15% of body weight over 12–18 months
• Strong cardiovascular outcome data (SELECT trial: 20% reduction in major cardiovascular events)

Best suited for: Individuals new to GLP-1 therapy, those who prefer the most extensively studied option, or those with cardiovascular risk who benefit from semaglutide's established cardioprotective data.

Tirzepatide: The Dual Agonist

Tirzepatide represented a significant leap forward by adding GIP receptor agonism to GLP-1 activity. The SURMOUNT trials demonstrated substantially greater weight loss than semaglutide, with participants achieving an average of 20.9% body weight reduction at the highest dose (15 mg weekly) over 72 weeks — and some individuals losing more than 25% of their body weight.

Key characteristics of tirzepatide:

• Dual mechanism: GLP-1 + GIP receptor agonism
• Superior weight loss efficacy compared to semaglutide in head-to-head trials (SURMOUNT-5)
• Weekly subcutaneous injection
• Average weight loss: 18–22% of body weight over 12–18 months
• Favorable effects on insulin sensitivity, lipid panels, and blood pressure
• Growing body of cardiovascular and metabolic outcome data

Best suited for: Individuals who did not achieve satisfactory results on semaglutide, those with higher baseline body weight, or those who want maximum efficacy from a dual-agonist approach.

Retatrutide: The Triple Threat

Retatrutide is the newest and most potent of the three. By adding glucagon receptor agonism to both GLP-1 and GIP activity, it introduces a third mechanism specifically targeting energy expenditure and hepatic fat metabolism. Phase 2 trial data showed participants achieving an extraordinary average of 24.2% body weight reduction at 48 weeks — with the highest-dose group averaging over 26% — numbers previously only seen with bariatric surgery.

Key characteristics of retatrutide:

• Triple mechanism: GLP-1 + GIP + Glucagon receptor agonism
• Highest weight loss efficacy of any injectable GLP-1 class compound in trials to date
• Weekly subcutaneous injection
• Average weight loss: 22–26%+ of body weight over 12 months in Phase 2 data
• Pronounced effects on liver fat (particularly beneficial in non-alcoholic fatty liver disease)
• Still in clinical development; Phase 3 data ongoing

Best suited for: Individuals with significant obesity who have not responded adequately to semaglutide or tirzepatide, those with metabolic syndrome or fatty liver disease, or those seeking maximum possible weight loss short of surgical intervention.

Side Effect Comparison

All three compounds share a core side effect profile driven by their GLP-1 mechanism, with intensity generally increasing alongside potency:

• Gastrointestinal effects: Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are the most common adverse events across all three. These are most pronounced during dose escalation and typically improve as the body adapts.
• Injection site reactions: Mild redness, bruising, or discomfort at the injection site can occur with any injectable peptide.
• Muscle mass: A meaningful proportion of weight lost on GLP-1 agonists can be lean mass. Resistance training and adequate protein intake (1.6–2.2 g/kg of body weight) are strongly recommended on any of these protocols.
• Retatrutide-specific: The glucagon agonism in retatrutide may produce slightly more pronounced increases in heart rate compared to the other two compounds, and its effect on liver enzyme profiles requires monitoring.

Protocol Guidelines

Starting Doses and Titration

All three compounds require gradual dose escalation to minimize GI side effects. Rushing titration is the most common reason people discontinue these medications prematurely.

• Semaglutide: Begin at 0.25 mg/week for 4 weeks, increase to 0.5 mg/week, then escalate in 0.5 mg steps every 4 weeks as tolerated, targeting 1.7–2.4 mg/week.
• Tirzepatide: Begin at 2.5 mg/week for 4 weeks, increase to 5 mg, then escalate in 2.5 mg steps every 4 weeks, targeting 10–15 mg/week.
• Retatrutide: Begin at 1–2 mg/week, escalate slowly every 4 weeks as tolerated, targeting 8–12 mg/week based on individual response and tolerability.

Which Should You Choose?

The honest answer depends on your individual goals, health history, and how your body responds. A sensible framework:

• Choose semaglutide if you want the most clinical data, the safest known cardiovascular profile, and a proven starting point.
• Choose tirzepatide if you want meaningfully superior weight loss efficacy, particularly if you have insulin resistance or metabolic syndrome alongside your weight management goals.
• Choose retatrutide if you have significant obesity (BMI 40+), have not responded adequately to other GLP-1 therapies, or have a strong indication like non-alcoholic fatty liver disease that benefits from the glucagon component.

VORN carries all three compounds: Semaglutide, Tirzepatide, and Retatrutide. Many clients also pair these with MOTS-C for enhanced metabolic effects and energy expenditure.

Frequently Asked Questions

Can I switch between these compounds?

Yes. Switching between GLP-1 agonists is common practice when one compound produces inadequate results or poor tolerability. Allow a brief washout period and restart the new compound at its lowest titration dose to minimize GI side effects.

Will I regain weight when I stop?

Weight regain after discontinuation is well-documented across all GLP-1 agonists. These compounds treat obesity as a chronic condition — the benefits persist only as long as treatment continues. Many patients remain on maintenance doses long-term.

How does diet interact with these medications?

GLP-1 agonists work best when combined with a caloric deficit and adequate protein intake. They reduce appetite, making adherence to a caloric deficit significantly easier, but they do not replace the need for reasonable dietary habits.

Are these compounds safe for people without diabetes?

Yes. Semaglutide and tirzepatide have been specifically approved for chronic weight management in non-diabetic individuals with obesity. The GLP-1-driven insulin secretion is glucose-dependent, meaning it does not cause hypoglycemia in normoglycemic individuals.